In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The close-knit South Shore village scored points for its strong public schools, quick commute to NYC and nearby beach access, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...